Is Nexplanon (etonogestrel) safe for a patient with a history of stroke?

Nexplanon is Safe for Patients with a History of Stroke

Nexplanon (etonogestrel implant) is a safe and appropriate contraceptive option for patients with a history of stroke, as it is a progestin-only method that does not increase stroke risk. 1

Evidence Supporting Safety

Progestin-Only Contraceptives Do Not Increase Stroke Risk

• The 2024 American Heart Association/American Stroke Association guidelines explicitly classify progestin implantation (etonogestrel) as having "None" increase to stroke risk with >99% contraceptive effectiveness. 1

• A meta-analysis of progestin-only contraceptives found no association with increased stroke risk (OR=0.96; 95% CI: 0.70-1.31), regardless of route of administration (implant, injectable, or oral). 2

• The stroke risk associated with progestin-only methods contrasts sharply with combined hormonal contraceptives containing estrogen, which show a dose-dependent linear relationship with stroke risk (OR 1.19 per 10 μg estrogen increase). 1

Guideline Recommendations

• The 2024 AHA/ASA guidelines state that "progestin-only contraception or nonhormonal contraception is reasonable to prevent the increased stroke risk associated with estrogen-containing contraception" in women requiring contraception. 1

• The U.S. Medical Eligibility Criteria for Contraceptive Use classifies progestin implants appropriately for various medical conditions, with no contraindication for history of stroke. 3

Key Distinction: Estrogen vs. Progestin

Why Nexplanon is Different

• Nexplanon contains only etonogestrel (a progestin) and no estrogen. 4

• The increased stroke risk with hormonal contraception is specifically attributable to the estrogen component in combined hormonal contraceptives, not progestins. 1

• Combined oral contraceptives with ≥30 μg ethinyl estradiol show moderate to severe increases in stroke risk (++ to +++ risk), while progestin-only methods show none. 1

FDA Safety Information

Thrombotic Events Warning Context

• The FDA label for Nexplanon mentions that "the use of combination hormonal contraceptives (progestin plus estrogen) increases the risk of vascular events" but explicitly states "NEXPLANON is a progestin-only contraceptive. It is unknown whether this increased risk is applicable to etonogestrel alone." 4

• Postmarketing reports of thrombotic events exist, but these must be interpreted in context: women with a history of thromboembolic disorders should be made aware of the possibility of recurrence, which is a general precaution rather than a contraindication. 4

• The FDA label does not list history of stroke as a contraindication to Nexplanon use. 4

Clinical Approach for Patients with Stroke History

Assessment Before Placement

• Evaluate the type of prior stroke (ischemic vs. hemorrhagic) and underlying etiology. 5

• Assess current stroke risk factors: hypertension, smoking, diabetes, hyperlipidemia, and ensure these are optimally managed. 1

• Confirm the patient is not in the acute post-stroke period: avoid placement in the immediate weeks following stroke when thrombotic risk may be elevated. 4

Contraindications to Consider

Nexplanon should not be used if the patient has: 4

• Active or recent thrombotic events (deep vein thrombosis, pulmonary embolism within recent months)
• Known thrombophilic disorders with high recurrence risk
• Unexplained vaginal bleeding or breast cancer
• Active liver disease or liver tumors

Monitoring After Placement

• Monitor blood pressure if the patient has hypertension, as this is a stroke risk factor independent of contraceptive choice. 4

• Counsel about warning signs: sudden severe headache, vision changes, chest pain, leg swelling, or neurological symptoms warrant immediate evaluation. 4

• Consider removal if thrombosis occurs, though this is a rare event with progestin-only methods. 4

Common Pitfalls to Avoid

• Do not confuse progestin-only contraceptives with combined hormonal contraceptives: The stroke risk data for combined oral contraceptives does not apply to Nexplanon. 1, 2

• Do not withhold effective contraception unnecessarily: Pregnancy itself carries a stroke risk of 30 per 100,000 pregnancies, which is higher than the stroke rate in women using progestin-only contraception. 1

• Do not overlook alternative explanations for thrombotic events: In patients with prior stroke, recurrent events may be related to underlying vascular disease, not the contraceptive method. 4

Alternative Considerations

If there is concern about any hormonal method, non-hormonal options include: 1

• Copper IUD (>99% effective, no stroke risk)
• Barrier methods (condoms, diaphragm)
• Surgical sterilization (>99% effective, no stroke risk)

However, these alternatives should be weighed against the superior efficacy and convenience of Nexplanon (>99% effective) and the lack of evidence for increased stroke risk with progestin-only methods. 1, 2